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serum	25-	hydroxyvitamin	D	 (25(OH)D3),	 and	 1,25(OH)2D3	 concentrations	 to	mild	
cognitive	impairment	(MCI)	and	various	stages	of	Alzheimer’s	disease	(AD).
Materials and Methods: The study included 230 participants (>74 years) allocated to 
three	main	groups:	1-	healthy	subjects	(HS,	n	=	61),	2-	patients	with	MCI	(n	=	61),	and	
3-	patients	with	Alzheimer’s	disease	(AD)	subdivided	into	three	stages:	mild	(n	=	41),	
moderate (n	=	35),	and	severe	AD	(n = 32). The cognitive status was evaluated using 
MMSE.	Serum	25	(OH)D3	(ng/ml)	and	1,25(OH)2D3	concentrations	(pg/ml)	were	de-
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degree of accuracy if dementia is diagnosed using a cognitive score 
(Creavin	et	al.,	2016;	Votruba,	Persad,	&	Giordani,	2016).	 In	addition	
to	 age	 and	 gender,	 the	Mini-	Mental	 State	Examination	 (MMSE)	 has	
been regarded as a useful instrument for evaluating the cognitive state 
of	patients	 (Folstein,	Folstein,	&	McHugh,	1975)	and	used	as	a	pre-
dictor	of	AD	(Musicco	et	al.,	2009).	Mild	cognitive	 impairment	(MCI)	





In	 addition	 to	 its	 known	 significance	 in	 bone	 and	 calcium	 ho-
meostasis,	vitamin	D	 improves	protein	homeostasis	and	slows	aging	
(Mark	et	al.,	2016).	The	enzymes	involved	in	conversion	of	25(OH)D3 
to	1,25(OH)2D3	 are	 all	 present	 in	 the	brain	 (Harms,	Burne,	 Eyles,	&	
McGrath,	2011).	There	is	a	reciprocal	relationship	between	vitamin	D	






neuronal	 plasma	membrane	 (Dursun	&	Gezen-	Ak,	 2017).	Amyloid	β 
(Aβ),	 the	 pathological	 hallmark	 of	AD,	 degrades	 vitamin	D	 receptor	
(Dursun,	Gezen-	Ak,	&	Yilmazer,	2010).	Vitamin	D	decreases	the	bur-









trol subjects. These include decreased metabolism of fluorodeoxy-
glucose	 (Silverman	 et	al.,	 2001),	 increased	 uptake	 of	 amyloid	 (Small	
et	al.,	 2006),	 elevated	 levels	 of	 tau	 or	 its	 phosphorylated	 form,	 and	
decreased amyloid β42	 in	 CSF	 (Hansson	 et	al.,	 2006;	 Querfurth	 &	
LaFerla,	2010;	Sunderland	et	al.,	 2003).	However,	 these	approaches	
are	either	 invasive	or	very	expensive.	Therefore,	 there	 is	still	a	need	




and	various	 stages	 (mild,	moderate,	 and	 severe)	 of	AD.	Accordingly,	
this	study	was	conducted	to	evaluate	utility	of	MMSE,	serum	25(OH)
D3,	and	1,25(OH)2D3 concentrations in prediction and diagnosis pa-
tients	with	MCI	and	the	various	stages	of	AD.
2  | MATERIALS AND METHODS
2.1 | Participants
A	total	of	230	individuals	from	Fukuoka	University	Hospital	were	in-






nitive	 impairment	 in	 patients	 with	 AD	was	 evaluated	 using	MMSE	
scores:	mild	AD	(27	≥	MMSE	>	20),	moderate	AD	(20	≥	MMSE	>	10),	
and	 severe	 AD	 (10	>	MMSE)	 (Feldman,	 Van	 Baelen,	 Kavanagh,	 &	
Torfs,	2005;	O’Bryant,	Humphreys,	&	Smith,	2008).	Each	participant	
was clinically evaluated by set of tests that included questionnaire and 
a	proxy	interview,	assessment	of	past	and	present	illness,	neurological	
and	physical	 examinations,	blood	chemistry,	 and	neuroimaging	with	







between	women	moderate	AD	compared	to	women	HS	(p = .23) and 
men	HS	(p = .013). The respective ages (year) of women and men were 
as	follows:	HS	(74.5	±	6.3;	74.4	±	8.7),	MCI	(75.5	±	6.8,	77.7	±	11.2),	
mild	AD	(74.8	±	8.1;	78.3	±	6.3),	moderate	AD	(82.2	±	5.1;	76.9	±	7.6),	
and	 severe	 AD	 (77.7	±	8.7;	 76.5	±	9.1).	 A	 difference	 was	 detected	
only	between	moderate	AD	women	and	HS	women	(p = 0.031),	and	
between	 moderate	 AD	women	 and	 moderate	 AD	men	 (p = 0.016). 
This difference is consequent to grouping according to the clinical 
classification	to	MCI	or	AD.	All	participants	were	free	of	hepatic	and	
renal disorders. The ethical permission for this study was obtained 
from	the	ethical	committee	of	Fukuoka	University	Hospital.	The	study	
was performed in accordance with the ethical standards of the 1964 
Helsinki	Declaration.	Written	informed	consent	was	obtained	from	all	
participants or their relatives prior to their participation in the study. 
We excluded participants with any present or earlier history of vita-
min	D	supplementation.
2.2 | Samples preparations and analyses
Peripheral blood was collected from each participant and cen-
trifuged at 400 x g for 20 min. The sera obtained were stored at 
−80°C	 until	 use.	 Total	 serum	 concentrations	 of	 25(OH)D3 and 
1,25(OH)2D3 were determined by competitive radioimmunoassay 
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using	 two	 respective	 antibodies.	A	 25-	OH	 vitamin	D	 125I	 RIA	Kit	
(DiaSorin	Inc.	MN,	USA)	was	used	to	assay	25(OH)D3.	Briefly,	after	
pretreatment of the samples with acetonitrile 300 to remove pro-
teins,	 the	 sample	 extracts	 containing	 25(OH)D3 were incubated 
with 125I-	25(OH)D3	and	sheep	anti-	25(OH)D3 antibody for 90 min 
at	 room	 temperature.	 Cellulose-	conjugated	 anti-	sheep	 IgG	 anti-
body was added to the precipitated reactive complex and free 125I-	
25(OH)D3 was removed by centrifugation. The radioactivity in each 




principle of this assay system was the same as that above except a 
column technique was also employed to remove lipids during sam-
ple pretreatment.
2.3 | Statistical analyses
ANOVA	 one-	way	 was	 conducted	 on	 the	 variables	 (age,	 MMSE,	
25(OH)D3	 and	 1,25(OH)2D3)	 between	 groups	 (HS,	 MCI,	 mild	 AD,	
moderate	 AD	 and	 severe	 D),	 with	 gender	 as	 covariate,	 to	 detect	
the	 following:	 1-	the	main	 effect,	 differences	 between	 the	 variables	
of	 the	groups,	2-	The	groups	within	each	gender,	and	each	gender’s	
variable between groups were compared to evaluate the effects of 
gender.	Homogeneity	was	verified.	Tukey’s	multiple	comparisons	post	
hoc	 test	was	 applied	whenever	ANOVA	detected	 significant	differ-
ences.	Bivariate	correlations	among	the	variables	were	evaluated	by	
Pearson’s	correlation	coefficient.	As	MMSE	could	be	seen	as	both	risk	
factor	 and	outcome	of	 the	disease,	 a	 linear	 regression	 analysis	was	
also	 conducted	 to	 determine	 the	 regression	 coefficients,	 statistical	
significance of regression model (t	 value),	 and	proportion	of	MMSE	
(dependent)	 contributed	 by	 independent	 variables	 (age,	 gender,	
25(OH)D3,	 and	1,25(OH)2D3)	derived	 from	 the	multiple	 correlation	
coefficient	(Adjusted	R2).
The predictors were also tested with univariate logistic regression 
analyses to assess the contribution of each predictor alone to each 
group.	Then,	multivariate-	forward	selection	analyses	were	conducted	
to assess the contribution of the predictors in combination to in-
crease the statistical power and account for the individual differences 
in	prediction.	Variables	which	had	a	p value of >.05 were excluded. 
The followings were calculated: β: logistic regression coefficient de-
scribes	the	size	and	direction	of	the	relationship	between	a	predic-
tor and the disease (predictive value). Positive predictive value is the 
probability that a subject classified as a patient by the test belongs 
in the patient group becomes more likely as the predictor increases. 
Negative	predictive	value	is	the	probability	that	a	subject	classified	as	
a	nonpatient	by	the	test	belongs	in	the	nonpatient	group.	It	also	indi-
cates the inverse relationship between the predictor and the disease 
(decreased	predictor	means	 increased	disease	odd).	Odd	ratio	 (OR):	
the	ratio	of	the	odds,	calculated	as	the	exponent	of	β.	OR	is	the	mea-
surement of likelihood and indicates that when the predictor is raised 
by one unit the odds ratio of the outcome increase by a factor equal 
to	 the	OR	value,	 that	 is,	 the	odds	of	participants	 in	 the	dependent	
variable	 (patients)	 increase	by	a	 factor	equivalent	 to	OR	value	with	
95%	confidence	interval	(CI).	Correct	classification,	CC	(accuracy	rate	
(%)	 of	 the	 predictor	 to	 diagnose	or	 distinguish	 two	 compared	vari-
ables),	 and	Wald	value	 (significance	of	predictor	 contribution)	were	
also measured.
Receiver	operating	characteristic	(ROC)	analysis	provides	useful	




optimal balance of sensitivity and specificity can be obtained were 
derived	 according	 to	Youden	 Index.	 Sensitivity	 (with	 optimal	 95%	
confidence interval) is the probability that a test result will be posi-
tive when the disease is present (true positive rate—the probability 
that a patient will be accurately classified by the test). Specificity 
(with	optimal	95%	confidence	interval)	 is	probability	that	a	test	re-
sult will be negative when the disease is not present (true negative 





the	more	 true	 positive	 is	 the	 result.	 The	 positive	 (LR+)	 and	 nega-
tive	 (LR−)	 likelihood	 ratios	 are	 probabilities	 of	 respective	 positive	









3.1 | MMSE scores in patients with MCI and AD
The	MMSE	scores	of	HS	women	and	men	were	28.0	±	1.9,	29.1	±	0.9,	
respectively.	 Figure	1	 shows	 that	MMSE	 scores	 were	 decreased	 in	
MCI	 and	AD.	A	 significant	 difference	 for	 the	main	 effect,	 between	




16.1	±	2.5,	men	 17.5	±	2.0),	 and	 severe	 AD	 (women	 4.6	±	4.1,	men	
4.5	±	3.4).	The	decrease	 in	MMSE	scores	 in	AD	was	more	than	that	
observed	in	MCI	 in	both	genders	(p = .000 for moderate and severe 
AD	vs.	MCI)	except	 in	mild	AD	 (women,	p = .030;	men,	p = .002 vs. 
MCI).	 In	 addition,	 significant	 differences	 (p = .000) were detected 
among	the	various	stages	of	AD	in	women	and	men	analyzed	sepa-
rately.	 However,	 no	 significant	 gender-	dependent	 difference	 was	
detected	for	the	same	stage	of	AD	between	women	and	men	when	
compared to each other.
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3.2 | Serum 25(OH)D3 concentrations in patients 
with MCI and AD
In	 HS,	 the	 mean	 serum	 concentrations	 of	 25(OH)D3 were 
26.18	±	7.18	ng/ml	 and	 27.42	±	8.05	ng/ml	 in	 women	 and	 men	
	participants,	 respectively.	 A	 significant	 (F(4,225)	=	25.869,	
p = .000)	main	 effect	 of	25(OH)D3	was	obtained	 in	MCI	 and	AD.	
Figure	2	shows	that	concentrations	of	25(OH)D3 in patients with 
MCI	 were	 lower	 than	 HS	 in	 both	 women	 (18.23	±	5.11	ng/ml;	
p = .000)	 and	 men	 (21.03	±	6.99	ng/ml;	 p = .003).	 However,	 the	
concentrations	 of	 25(OH)D3	 in	MCI	were	 not	 different	 from	AD	
in both genders.
Figure	2a	 shows	 that	 in	 AD	 women	 patients,	 25(OH)D3 con-
centrations	 in	 mild	 AD	 (17.75	±	5.30	ng/ml),	 moderate	 AD	
(16.79	±	5.32	ng/ml),	 and	 severe	 AD	 (13.95	±	5.08	ng/ml)	 were	
significantly	lower	than	HS	(p = .000).	On	the	other	hand,	it	can	be	
seen	 from	 Figure	2b	 that	 in	 the	men	 patients,	 the	 concentrations	
of	25(OH)D3 were significantly (p = .000)	lower	than	HS	in	mild	AD	
(17.59	±	6.95	ng/ml)	and	severe	AD	(15.36	±	4.08	ng/ml).	However,	
no significant (p = .105)	difference	was	detected	between	HS	and	
the	 moderate	 AD	 (21.09	±	6.32	ng/ml).	 No	 significant	 difference	
was	detected	among	the	AD	stages	for	the	same	gender,	or	between	
the genders in each group.
3.3 | Serum 1,25(OH)2D3 concentrations in patients 
with MCI and AD
In	 HS,	 the	 mean	 serum	 concentrations	 of	 1,25(OH)2D3 were 
53.05	±	13.04	pg/ml	 and	 54.12	±	14.34	pg/ml	 in	 women	 and	 men	
participants,	 respectively.	 Figure	3a	 shows	 that,	 in	 women,	 the	





AD),	 and	 48.25	±	9.55	pg/ml	 (severe	 AD).	 No	 significant	 difference	
among the groups was detected (F(4,225)	=	0.583,	p = .676).
3.4 | Correlations among MMSE, 25(OH)D3, and 
1,25(OH)2D3
Table	1	 and	 Figure	4	 show	 that	 no	 correlation	 was	 evident	 in	 HS.	
On	 the	 other	 hand,	 in	 MCI,	 the	 largest	 and	 significant	 correlation	
was	detected	in	men	between	25(OH)D3	and	1,25(OH)2D3 (r	=	.456,	
p = .011)	in	addition	to	the	correlation	between	25(OH)D3 and MMSE 
(r	=	.330,	p = .022),	and	1,25(OH)	2D3 (r	=	−.356,	p = .048). The total 
correlation	between	25(OH)D3	and	1,25(OH)2D3	in	both	genders	was	
F IGURE  1 Box	plot	of	MMSE	scores	
in women (a) and men (b). The lower and 
upper sides of the boxes indicate the 
25th	and	75th	percentiles.	The	horizontal	
lines and black diamonds inside the 
boxes	indicate	the	median	and	means,	
respectively. Shown are also the lower and 
upper whiskers that indicate the minimum 
and	maximum	values,	respectively.	In	
women	HS,	the	upper	horizontal	bar	
outside the box with the whisker and 
the median line inside the box have not 








the whiskers have not appeared in men 
HS.	The	levels	of	statistically	significant	
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F IGURE  2 Box	plot	of	serum	
concentrations	of	25(OH)D3 in women (a) 
and	men	(b)	HS,	MCI	and	AD.	The	lower	
and upper sides of the boxes indicate the 
25th	and	75th	percentiles.	The	horizontal	
lines and black diamonds inside the 
boxes	indicate	the	median	and	means,	
respectively. Shown are also the lower and 
upper whiskers that indicate the minimum 
and	maximum	values,	respectively.	The	





















































































concentrations	of	1,25(OH)D3 in women 
(a) and men (b). The lower and upper sides 
of the boxes indicate the 25th and 75th 
percentiles.	The	horizontal	lines	and	black	
diamonds inside the boxes indicate the 
median	and	means,	respectively.	Shown	
are also the lower and upper whiskers 
that indicate the minimum and maximum 
values,	respectively.	No	significant	
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significant (r	=	.254,	p = .05).	No	significant	correlation	was	observed	
in	women	with	MCI.
In	patients	with	AD,	significant	correlations	were	detected	only	
in	 women.	 MMSE	was	 correlated	 only	 with	 25(OH)D3 in moder-
ate	 AD	 (r	=	−.326,	 p = .048)	 and	 severe	 AD	 (r	=	−.331,	 p = .023),	
indicating	to	a	parallel	decrease	of	MMSE	with	25(OH)D3,	but	not	
1,25(OH)2D3.	 On	 the	 other	 hand,	 the	 largest	 correlation	was	 de-
tected	between	25(OH)D3	and	1,25(OH)2D3	 in	severe	AD	(r = .62; 
p = .003)	 followed	 by	 mild	 AD	 (r	=	.487,	 p = .016). There was no 
significant	 correlation	 between	 25(OH)D3	 and	 1,25(OH)2D3 in 
moderate	AD	(r	=	.357,	p = .087).	The	correlation	of	25(OH)D3 and 
1,25(OH)2D3 values of all stages together was significant in women 
(r	=	.488,	p = .016) but not in men (r	=	.114,	p = .710). The total cor-
relation	between	25(OH)D3	and	1,25(OH)2D3 for both genders was 
not significant (r	=	.301,	p = .372).
The linear regression established that only gender could signifi-
cantly predict MMSE (B	=	0.325,	t	=	2.638,	p = .011) and account for 
11%	(adjusted	R2)	of	MMSE	variability	 in	HS.	On	the	other	hand,	al-
though	both	25(OH)D3	and	1,25(OH)2D3 contributed to MMSE vari-
ability	in	MCI,	1,25(OH)	2D3	accounted	for	only	3%	of	the	variability	
(p = .075),	while	25(OH)D3 significantly (p = .0001)	contributed	(16%)	
to	MMSE	variability.	On	the	other	hand,	in	AD,	only	25(OH)D3 could 
significantly (p = .000)	affect	MMSE	and	accounts	for	26%	of	MMSE	
variability (Table 2).




same or close sensitivity and specificity values. The highest cutoff 
value	 was	 obtained	 in	 MCI	 and	 AD	 when	 evaluated	 against	 HS.	
Moreover,	higher	LR+	and	lower	LR−	for	MMSE	were	observed	in	
MCI	and	mild	AD	combined	with	HS	(data	not	shown).	On	the	other	












Women 25 (OH)D3 1,25 (OH)2 D3 Men 25 (OH)D3 1,25 (OH)2 D3
HS	(n = 28) MMSE r .122 .147 HS	(n = 33) MMSE r −.139 −.134
p .535 .258 p .441 .457
25(OH)D3 r 1 −.041 25(OH)D3 r 1 −.248
p — .836 p — .165
MCI	(n = 31) MMSE r −.016 −.288 MCI	(n = 30) MMSE r .330 −.365
p .932 .115 p .022* .048*
25(OH)D3 r 1 .082 25(OH)D3 r 1 .456
p — .66 p — .011*
Mild	AD	
(n = 24)
MMSE r −.086 −.099 Mild	AD	
(n = 17)
MMSE r .052 −.275
p .689 .645 p .842 .285
25(OH)D3 r 1 .487 25(OH)D3 r 1 .163
p — .016* p — .531
Moderate	AD	
(n = 24)
MMSE r −.326 .148 Moderate	AD	
(n = 11)
MMSE r −.415 −.280
p .048* .49 p .205 .404
25(OH)D3 r 1 .357 25(OH)D3 r 1 .156
p — .087 p — .647
Severe	AD	
(n = 21)
MMSE r −.331 .239 Severe	AD	
(n = 11)
MMSE r .138 .056
p .023* .297 p .687 .87
25(OH)D3 r 1 .62 25(OH)D3 r 1 .024
p — .003* p — .944
The correlation coefficient magnitude (r)	is	determined	according	to	Pearson’s	correlation:	small	(r	=	.1),	medium	(r	=	.3),	and	large	(r = >.5).
*Significant correlation.
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3.6 | Univariate and multivariate logistic 
regression analyses
The	prediction	values	were	evaluated	for	each	of	MCI	and	AD	groups	
against	 HS.	 Univariate	 analysis	 of	 each	 predictor	 alone	 (Table	4)	
shows that significant (p = .0001) prediction by age (β	=	+0.133;	
Wald	=	12.12;	 OR	=	1.143;	 CC	=	71%;	 p = .0001) and gender 
(β	=	−0.944;	Wald	=	4.49;	OR	=	0.389;	 CC	=	64%;	p = .034) was ob-
tained	in	moderate	AD.	These	results	indicate	that	for	each	one	unit	
increase	of	age	(1	year),	the	odds	of	disease	risk	 increases	by	1.143	
(53%	 probability).	 In	 case	 of	 gender,	 women	 were	 considered	 as	
the	reference.	In	other	words,	the	negative	value	of	β indicates that 
women have 2.6 (1/0.389 = 2.6) times the risk of the disease than 
men.	Moreover,	 it	 can	 also	 be	 seen	 from	 Table	4	 that	 a	 significant	
(p	=	.0001)	 prediction	 by	MMSE	was	 observed	 in	MCI	 (β	=	−1.324,	




and	Wald	 values	were	 detected	 for	 25(OH)D3	 in	MCI	 (β	=	−0.146,	
Wald	=	22.044,	 OR	=	0.864,	 46%	 probability),	 mild	 AD	 (β	=	−0.188,	
Wald	=	22.744,	 OR	=	0.829,	 45%	 probability),	 moderate	 AD	
(β	=	−0.178,	Wald	=	20.04,	OR	=	0.837,	46%	probability),	and	severe	
AD	(β	=	−0.316,	Wald	=	20.821,	OR	=	0.729,	42%).	These	results	indi-





Table 4 shows that univariate analysis of all groups collectively re-
vealed the significant contribution of all the examined predictors. The 
maximum	Wald	(41.013)	and	CC%	(97.6%)	were	exhibited	by	25(OH)
D3	and	MMSE,	respectively.	Again,	multivariate	analysis	showed	that	




The	 present	 results	 show	 that	 MMSE	 and	 25(OH)D3 (but not 
1,25(OH)2D3)	 were	 decreased	 in	 MCI	 and	 various	 stages	 of	 AD.	
Although	MMSE	is	one	of	the	most	widely	used	tools	in	the	evaluation	
of	cognitive	status,	there	is	still	a	debate	about	its	diagnostic	accuracy.	
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et	al.,	1975).	MMSE	had	also	been	reported	to	predict	converters	to	
AD	(Devanand	et	al.,	2008;	Palmqvist	et	al.,	2012).	The	present	study	
highlights	the	value	of	MMSE	and	25(OH)D3 in the differential diag-
nosis	and	prediction	of	MCI,	mild	AD,	moderate	AD,	and	severe	AD	
at a sensitivity rate >80. The differences among the results reported 
for MMSE could be attributed to the analyses approach such as selec-
tion	of	the	cutoff	values,	and	the	patients’	cultural,	education,	and	de-
mographic	specificities.	It	is	also	noteworthy	to	mention	that	MMSE	
could	be	 influenced	by	 changes	 that	 could	 accompany	dementia.	A	
low level of the MMSE score is associated with low plasma phosphate 
(Haglin	&	Backman,	2016).
Vitamin	D3	 is	produced	 in	 the	skin	 from	7-	dehydrocholesterol	
under	 the	 influence	of	UV	 light.	Vitamin	D	 is	metabolized	 first	 to	
25(OH)D3	 in	 the	 liver,	 then	 undergoes	 1α- hydroxylation to the 
hormonal	 form	1,25(OH)2D3	 in	 the	 kidney	 (Bikle,	 2014).	The	 rela-
tion	 of	 25(OH)D3	 and	 1,25(OH)2D3 is farther than that between 
a	 substrate	 and	 its	 product.	 25(OH)D3	 and	 1,25(OH)2D3 are syn-
thesized,	 regulated,	 and	 changed	 differently	 in	 variable	 diseases.	
While	 25(OH)D3	 is	 mainly	 synthesized	 by	 CYP2R1	 (endoplasmic	
reticulum),	CYP27B1	 (mitochondrial)	 is	 the	main	 enzyme	 involved	
in	the	synthesis	of	1,25(OH)2D3.	The	independence	of	1,25(OH)2D3 
concentration	from	that	of	its	precursor	(25(OH)D3) is expected and 
could be attributed to their different kinetics and regulation. While 
25(OH)D3 (prehormone) concentration is increased by a high dose 
of	vitamin	D,	plasma	levels	of	1,25(OH)2D3 (adaptive hormone) ap-
peared	 to	 fall	with	 increasing	doses	of	vitamin	D,	 presumably	be-
cause	 the	1-	hydroxylase	 system	 is	 shut	 down	 (Jones,	 Strugnell,	&	
DeLuca,	1998).	1,25(OH)2D3 inhibits its own synthesis and that of 
its	precursor	25(OH)D3	(Bell,	Shaw,	&	Turner,	1984).	It	has	been	re-
ported	that	1,25(OH)2D3 kinetics do not change by aging in healthy 
men	 and	women	 (Eastell	 et	al.,	 1991;	Halloran,	 Portale,	 Lonergan,	
&	Morris,	1990).	The	production	of	1,25(OH)2D3	could	take	place	
extrarenally	and	regulated	endocrinologically.	 It	has	been	reported	
that	 1,25(OH)2D3 is increased by parathyroid hormone (Eastell 
et	al.,	1991)	and	cytokines,	 including	TNF	(Bikle	&	Vitamin,	2014).	
However,	serum	25(OH)D3	is	negatively	correlated	with	TNFα,	IL-	1β 
or	 IL-	6	 levels	 in	healthy	subjects	and	patients	with	MCI,	but	posi-
tively	with	late-	onset	AD	(Dursun	et	al.,	2016).	As	TNF	is	increased	
in	AD	(Gezen-	Ak	et	al.,	2013),	it	is	possible	that	the	increased	TNFα 
is	 responsible	 for	 the	 decreased	 25(OH)D3. These mechanisms 
could	play	a	role	in	maintaining	1,25(OH)2D3 level against reduced 
25(OH)D3.
The	serum	vitamin	D	 level	 is	associated	with	 its	activity	 in	 the	
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2009;	Yu	et	al.,	2011).	On	the	other	hand,	 low	serum	25(OH)D3 is 
associated	with	neuronal	damages	(Gezen-	AK,	Yilmazer,	&	Dursun,	
2014),	 MCI	 (Annweiler	 et	al.,	 2012),	 multidomain	 MCI	 (Yin	 et	al.,	
2015)	 and	 AD	 (Annweiler	 et	al.,	 2015;	 Balion,	 Griffith,	 &	 Strifler,	
2012;	 Chei	 et	al.,	 2014;	 Littlejohns,	 Henley,	 &	 Lang,	 2014).	 The	




nostic power when the evaluation was carried out among the stages 
of	AD.	 It	 should	be	noted	 that	although	25(OH)D3 was decreased 
in	MCI	and	AD,	no	difference	was	observed	between	women	and	
men	but	it	predicted	a	2.5	times	higher	incidence	of	AD	in	women	




of	1,25(OH)2D3;	 hence,	 serum	1,25(OH)2D3 concentration did not 
vary	among	HS	and	participants	with	MCI	or	AD.	No	change	 in	1,	
25(OH)2D3	adds	to	the	fact	that	concentration	of	1,25(OH)2D3 is not 
a	reliable	marker	in	AD.	Another	finding	of	this	study	was	that	serum	
1,25(OH)2D3	and	25(OH)D3 concentrations were not correlated in 
the	HS	group.	It	is	noteworthy	to	mention	that	while	25(OH)D3 and 
1,25(OH)2D3	 concentrations	were	 not	 correlated	 in	men	with	AD,	
they	were	positively	correlated	 in	women	patients	with	AD.	These	
results	may	be	associated	with	high	incidence	of	AD	in	women	and	
suggest	 gender	differences.	 It	 could	 also	 result	 from	possible	 lim-








Cut- offa Sensitivity SpecificityLower Bound Upper Bound
MCI	vs.	HS MMSE 0.906 0.03 0.0001* 0.847 0.965 27.5 0.82 0.984
25	(OH)D3 0.765 0.04 0.0001* 0.681 0.849 27.5 0.902 0.541
1,25(OH)2	D3 0.5 0.05 1.000 0.396 0.604 — — —
Mild	AD	vs.	
HS
MMSE 0.993 0.01 0.0001* 0.979 1 27.5 1 0.984
25	(OH)D3 0.815 0.04 0.0001* 0.736 0.895 25.5 0.927 0.574
1,25(OH)2	D3 0.41 0.06 0.124 0.293 0.527 — — —
Moderate	AD	
vs.	HS
MMSE 1 0 0.0001* 1 1 22 1 1
25	(OH)D3 0.812 0.04 0.0001* 0.725 0.899 27.5 0.943 0.541
1,25(OH)2	D3 0.472 0.06 0.645 0.351 0.593 — — —
Severe	AD	vs.	
HS
MMSE 1 0 0.0001* 1 1 17 1 1
25	(OH)D3 0.911 0.03 0.0001* 0.857 0.966 20.5 0.906 0.787




MMSE 1 0 0.0001* 1 1 20.5 1 1
25	(OH)D3 0.494 0.07 0.929 0.363 0.626 — — —
1,25(OH)2	D3 0.566 0.07 0.327 0.436 0.695 — — —
Severe	AD	vs.	
Mild	AD
MMSE 1 0 0.0001* 0 0 15.5 1 1
25	(OH)D3 0.661 0.06 0.019* 0.538 0.785 21.5 0.341 0.969




MMSE 1 0 0.0001* 1 1 10.5 1 1
25	(OH)D3 0.675 0.07 0.014* 0.546 0.804 21.5 0.314 0.969
1,25(OH)2	D3 0.515 0.07 0.836 0.374 0.655 — — —
Total	AD	vs.	
HS
MMSE 0.997 0.003 0.0001* 0.992 1 27.5 1 0.984
25	(OH)D3 0.843 0.03 0.0001* 0.782 0.904 20.5 0.741 0.787
1,25(OH)2	D3 0.455 0.05 0.327 0.366 0.543 — — —
AUC,	area	under	the	ROC	curve;	CI,	confidence	interval;	SE,	standard	error	of	AUC.
aCutoff	values	at	which	optimal	balance	of	sensitivity	and	specificity	can	be	obtained	according	to	Youden’s	index;	Youden’s	Index	can	be	calculated	as	the	
sum of sensitivity plus specificity minus 1 for all possible cutoff points.
*Sig,	significance	of	AUC.
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TABLE  4 Logistic	regression	analyses	for	the	contribution	of	the	individual	and	combined	predictors





Age 0.033 0.023 1.976 0.16 1.034 0.987 1.082 57.4
Gender −0.197 0.363 0.295 0.587 0.821 0.403 1.672 52.5
MMSE −1.324 0.251 27.858 0.0001* 0.266 0.163 0.435 90.2
25	(OH)D3 −0.146 0.031 22.044 0.0001* 0.864 0.813 0.918 70.2
1,25(OH)2	D3 0.005 0.011 0.251 0.616 1.005 0.985 1.026 50.8
B-	Multivariate
MMSE −1.445 0.295 24.041 0.0001* 0.236 0.132 0.42 88.5
25	(OH)D3 −0.168 0.047 12.644 0.0001* 0.846 0.771 0.927
Mild AD- HS
A-	Univariate
Age 0.033 0.028 1.41 0.235 1.033 0.979 1.091 61.8
Gender −0.509 0.408 1.557 0.212 0.601 0.27 1.337 59.8
MMSE −2.162 0.554 15.22 0.0001* 0.115 0.039 0.341 96.1
25	(OH)D3 −0.188 0.039 22.744 0.0001* 0.829 0.767 0.895 71.6
1,25(OH)2	D3 0.021 0.013 2.578 0.108 1.021 0.995 1.048 61.8
Moderate AD- HS
A-	Univariate
Age 0.133 0.038 12.119 0.0001* 1.143 1.06 1.231 70.8
Gender −0.944 0.446 4.492 0.034* 0.389 0.162 0.931 63.5
MMSE −0.053 846.038 0 0.992 0 0 0 100
25	(OH)D3 −0.178 0.04 20.04 0.0001* 0.837 0.774 0.905 75
1,25(OH)2	D3 0.008 0.016 0.256 0.613 1.008 0.978 1.039 63.5
Severe AD- HS
A-	Univariate
Age 0.048 0.029 2.628 0.105 1.049 0.99 1.111 66.7
Gender −0.811 0.452 3.215 0.073 0.444 0.183 1.078 65.6
MMSE −0.456 397.131 0 0.995 0.086 0 0 100
25	(OH)D3 −0.316 0.069 20.821 0.0001* 0.729 0.636 0.835 78.5
1,25(OH)2	D3 0.012 0.013 0.86 0.354 1.012 0.987 1.037 67.7
All participants
A-	Univariate
Age 0.059 0.021 7.502 0.006* 1.06 1.017 1.106 62.1
Gender −0.735 0.326 5.087 0.024* 0.48 0.253 0.908 63.9
MMSE −0.162 0.554 15.22 0.0001* 0.115 0.039 0.341 97.6
25(OH)D3 −0.213 0.033 41.013 0.0001* 0.808 0.757 0.863 79.9
1,25(OH)2	D3 0.013 0.01 1.635 0.201 1.013 0.993 1.033 63.9
B-	Multivariate
MMSE −2.83 1.022 7.662 0.006* 0.059 0.008 0.438 98.2
25(OH)D3 −0.207 0.173 2.262 0.0018* 0.813 0.579 1.141
β:	Logistic	regression	coefficient;	CC%:	correct	classification	%;	CI:	confidence	interval;	OR:	Odd	ratio	(Exponent	of	β),	Sig:	Logistic	Regression	p values for 
Wald.	Only	significant	variables	are	retained	in	the	B.	Disease	groups	were	tested	against	HS.	Predictor	power	was	evaluated	in	MCI	and	AD	tested	against	
HS.
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